Jennifer W. Carlisle
Papers
1
Total Citations
35
H-Index
1
About
Jennifer W. Carlisle is a leading translational researcher in thoracic oncology, with a focus on leveraging liquid biopsies to personalize treatment for non-small cell lung cancer (NSCLC). Her most-cited work, a 2021 study on dynamic circulating tumour DNA (ctDNA) response to neoadjuvant atezolizumab and surgery, has garnered 35 citations and represents a pivotal contribution to the field. Carlisle’s research centers on using ctDNA as a real-time biomarker to predict treatment outcomes, enabling earlier, non-invasive monitoring of therapeutic efficacy. By demonstrating that ctDNA dynamics correlate with pathological response and survival in NSCLC patients undergoing immunotherapy and surgery, she has provided a framework for adaptive clinical decision-making. Her work bridges the gap between molecular biology and clinical oncology, offering a pathway to reduce unnecessary toxicity and improve surgical outcomes. Carlisle’s achievements underscore her role in advancing precision medicine, making her a key voice in the integration of liquid biopsy into standard-of-care protocols for lung cancer. Her research continues to shape how clinicians assess response to neoadjuvant therapy, with implications for trial design and patient stratification.
Research Focus
Key Achievements
Top Papers
- 1